Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 319 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Better together: improving brain tumour treatment February 13, 2023 Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the... September 10, 2021 Dogs Can Sniff Out COVID-19 After Just One Week Of Training,... July 28, 2020 7 Steps for Developing Microhabits During Cancer That Can Improve Your... November 2, 2023 Load more HOT NEWS The power of partnership – the unique alliance taking on brain... EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ How Finding the Right Primary Care Physician During Cancer Has Helped...
